Use of Antifungal Combination Therapy: Agents, Order, and Timing
- PMID: 20574543
- PMCID: PMC2889487
- DOI: 10.1007/s12281-010-0018-6
Use of Antifungal Combination Therapy: Agents, Order, and Timing
Abstract
Given the substantial morbidity and mortality related to invasive fungal infections, treatment with a combination of antifungal agents is often considered. A growing body of literature from in vitro studies, animal models, and clinical experience provides data evaluating this approach. This review describes combination antifungal strategies for the management of cryptococcal meningitis, invasive candidiasis, invasive aspergillosis, and rare mold infections. The potential effects that sequencing and timing have on the efficacy of such approaches are discussed, with a focus on recent clinical data in this arena.
Similar articles
-
Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Drugs. 2009. PMID: 19275278 Review.
-
Combination antifungal therapy: what can and should we expect?Bone Marrow Transplant. 2007 Aug;40(4):297-306. doi: 10.1038/sj.bmt.1705687. Epub 2007 Jun 11. Bone Marrow Transplant. 2007. PMID: 17563740 Review.
-
Combination antifungal therapy for the treatment of invasive yeast and mold infections.Curr Infect Dis Rep. 2007 Nov;9(6):448-56. doi: 10.1007/s11908-007-0069-1. Curr Infect Dis Rep. 2007. PMID: 17999880
-
Combination antifungals: an update.Expert Rev Anti Infect Ther. 2007 Oct;5(5):883-92. doi: 10.1586/14787210.5.5.883. Expert Rev Anti Infect Ther. 2007. PMID: 17914921 Review.
-
Reassessment of the role of combination antifungal therapy in the current era.Curr Opin Infect Dis. 2024 Dec 1;37(6):443-450. doi: 10.1097/QCO.0000000000001063. Epub 2024 Sep 11. Curr Opin Infect Dis. 2024. PMID: 39259717 Review.
Cited by
-
Fungal burn wound infection caused by Fusarium dimerum: A case series on a rare etiology.Ann Med Surg (Lond). 2021 Sep 9;70:102848. doi: 10.1016/j.amsu.2021.102848. eCollection 2021 Oct. Ann Med Surg (Lond). 2021. PMID: 34540224 Free PMC article.
-
Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations.J Fungi (Basel). 2021 Feb 4;7(2):113. doi: 10.3390/jof7020113. J Fungi (Basel). 2021. PMID: 33557026 Free PMC article. Review.
-
Evaluation of bisphenylthiazoles as a promising class for combating multidrug-resistant fungal infections.PLoS One. 2021 Nov 4;16(11):e0258465. doi: 10.1371/journal.pone.0258465. eCollection 2021. PLoS One. 2021. PMID: 34735467 Free PMC article.
-
Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole.Mol Syst Biol. 2011 Jun 21;7:499. doi: 10.1038/msb.2011.31. Mol Syst Biol. 2011. PMID: 21694716 Free PMC article.
-
Candida albicans-The Virulence Factors and Clinical Manifestations of Infection.J Fungi (Basel). 2021 Jan 22;7(2):79. doi: 10.3390/jof7020079. J Fungi (Basel). 2021. PMID: 33499276 Free PMC article. Review.
References
-
- Lewis RE. Decision making in antifungal monotherapy versus combination therapy. Pharmacotherapy. 2006;26:61 S–67 S. - PubMed
-
- Lewis RE, Kontoyiannis DP. Rationale for combination antifungal therapy. Pharmacotherapy. 2001;21:149 S–164 S. - PubMed
-
- Kontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol. 2004;126:165–175. - PubMed
-
- Powers JH. Considerations in clinical trials of combination antifungal therapy. Clin Infect Dis. 2004;39(Suppl 4):S228–S235. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources